In this opening episode, we set the stage for the whole series by tracing the life-cycle of a drug: why it is pursued, how it is discovered, how it is tested, and what it takes to make it safely and ethically available to the public. We treat pharmacology as both a science and a social contract—where benefit must be proven, harm anticipated, and uncertainty handled with humility.
Key takeaways you’ll build and reuse throughout the series:
* The “drug journey” as a repeatable framework: target → lead compound → optimisation → preclinical evidence → clinical trials → approval → post-marketing vigilance.
* Why translation is hard: what works in a dish or animal doesn’t automatically work in humans, and why dose, exposure, and endpoints matter.
* Regulation as patient safety infrastructure, not bureaucracy: standards, approvals, and surveillance as the guardrails of public trust.
* Industry realities that shape practice: incentives, patents, pricing, marketing, and how they can help or distort therapeutic decision-making.
* A clinician’s lens: how to read claims critically, recognise bias, and keep the patient—not the product—at the centre of prescribing.
